BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.

doi:10.1038/srep17499

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.

Scientific reports - 7 Dec 2015

Karachaliou Niki, Codony-Servat Jordi, Teixidó Cristina, Pilotto Sara, Drozdowskyj Ana, Codony-Servat Carles, Giménez-Capitán Ana, Molina-Vila Miguel Angel, Bertrán-Alamillo Jordi, Gervais Radj, Massuti Bartomeu, Morán Teresa, Majem Margarita, Felip Enriqueta, Carcereny Enric, García-Campelo Rosario, Viteri Santiago, González-Cao María, Morales-Espinosa Daniela, Verlicchi Alberto, Crisetti Elisabetta, Chaib Imane, Santarpia Mariacarmela, Luis Ramírez José, Bosch-Barrera Joaquim, Felipe Cardona Andrés, de Marinis Filippo, López-Vivanco Guillermo, Miguel Sánchez José, Vergnenegre Alain, Sánchez Hernández José Javier, Sperduti Isabella, Bria Emilio, Rosell Rafael

Abstract excerpt

BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may influence response to EGFR TKI. We examined mRNA expression of BIM and MTOR in 57 patients with EGFR-mutant NSCLC from the EURTAC trial. Risk of mortality and disease progression was lower in patients with high BIM compared with low/intermediate BIM mRNA levels....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apoptosis Regulatory Proteins

Share to Bcl-2-Like Protein 11

Share to Disease-Free Survival

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Inhibitory Concentration 50

Share to Quinazolines

Share to TOR Serine-Threonine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 26639561
DOI: 10.1038/srep17499
PMCID: PMC4671004

Genes

EGFR
MTOR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.PMID 26639561Read ↗

Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC.Semantic proximity Read ↗

Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs.Semantic proximity Read ↗

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.Semantic proximity Read ↗

Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.Semantic proximity Read ↗

The BIM deletion polymorphism is a prognostic biomarker of EGFR-TKIs response in NSCLC: A systematic review and meta-analysis.Semantic proximity Read ↗

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas.Semantic proximity Read ↗

BIM Gene Polymorphism Lowers the Efficacy of EGFR-TKIs in Advanced Nonsmall Cell Lung Cancer With Sensitive EGFR Mutations: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.Semantic proximity Read ↗

EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP).Semantic proximity Read ↗

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.Semantic proximity Read ↗

Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.Semantic proximity Read ↗

Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.